However, Zhao et al. FGFR2 inhibitors added to HER2-positive breast cancer cells after the failure of treatment with the anti-HER2 drug lapatinib suggested a switch in cell addition to signaling inhibitors [53]. This evidence concerns the gene FGFR2 and breast cancer.